NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued on Thursday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Trading Up 8.1 %

NYSE:NBY opened at $0.53 on Thursday. The stock has a 50 day simple moving average of $0.60 and a 200 day simple moving average of $0.63. The stock has a market cap of $3.08 million, a P/E ratio of -0.01 and a beta of 0.90. NovaBay Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.